Update information
February 2014: Implementation section updated to clarify that azacitidine is recommended as an option for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
ISBN: 978-1-4731-3448-5
February 2014: Implementation section updated to clarify that azacitidine is recommended as an option for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
ISBN: 978-1-4731-3448-5